Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | PPARD | Q03181 | 5/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523618 | 0.82 | HIF1A (0.40) | ALOX5APPPARGPPARD | |
| SCHEMBL856144 | 0.81 | TBXA2R (0.39) | ALOX5APNR1H2PPARGNR1H3 | |
| SCHEMBL16150279 | 0.80 | CCNB2 (0.37) | NR1H2PPARGNR1H3 | |
| SCHEMBL1300216 | 0.76 | CNR2 (0.38) | NR1H2NR1H3 | |
| SCHEMBL31144615 | 0.75 | HTR6 (0.44) | NR1H2PPARGHDAC6NR1H3 | |
| SCHEMBL3756850 | 0.74 | CCNB2 (0.41) | NR1H2NR1H3PPARA | |
| SCHEMBL4527113 | 0.73 | CCNB2 (0.38) | NR1H2NR1H3PPARA | |
| SCHEMBL6743268 | 0.73 | MAP2K4 (0.42) | NR1H2 | |
| SCHEMBL20593183 | 0.72 | TBXA2R (0.37) | ALOX5APPPARGHDAC6 | |
| SCHEMBL10173079 | 0.71 | CCNB2 (0.39) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124563-B1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2124563-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| WO-2008076752-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | TRPV1, TRPV2, TRPA1 | ALOX5AP 571/4885NR1H2 947/4885IDO1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.